Endexx Global Operations in Jamaica Ready to Launch
CAVE CREEK, AZ, Dec. 03, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – Endexx Corporation, (OTC: EDXC) (the “Company” or a/k/a “CBD Unlimited”), a lifestyle company focused on the intersection of science, compliance, and formulation of innovative phytonutrient-based food and nutritional products is pleased to update shareholders on our global expansion plans.
In a historic vote in Vienna today, “The United Nations Commission on Narcotic Drugs (CND) accepted a World Health Organization (WHO) recommendation to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs.”
This World Health Organization recommendation and vote by the UN is the second critical stage to advancing legal changes on cannabis and hemp in all the Industrialized Nations that strictly comply with UN Law. This precedent allows countries like the US, Japan, and Korea to advance new guidelines and laws towards making medicinal cannabis and hemp fully compliant and legal both domestically and globally. As previously mentioned, this ruling opens the potential for banking, insurance, and commodity trading industries to build infrastructure for long-term industry success. Endexx has positioned itself to capitalize directly on this global growth opportunity.
CEO of Endexx, Todd Davis, a known pioneer in the industry, had previously predicted this would occur and recently added, “Domino number two, will change the cannabis industry forever. Cannabis, including Hemp, is no longer illegal and considered a dangerous narcotic and worldwide cannabis and CBD markets will exponentially expand the previously predicted market potential by 1000 fold. This promotes the advancement of Hemp and CBD products to become a worldwide accepted commodity and the potential for Endexx brands such as CBD Unlimited, to become a world leader in the marketplace.”
“Jamaica Is Endexx’s Global Market Gateway”
Endexx through its subsidiary, Go Green Global, has recently received two provisional licenses in Jamaica allowing for the sale, cultivation, processing, and distribution of cannabis upon final approval. Jamaica’s established history with Ganja, now fully legalized, offers a premium agricultural crop and export to unlock the value of its natural resources and globally positioned ports as the gateway for cannabis to the world markets. The UN vote allows Jamaican officials to expedite exportation compliance standards and open the Jamaican cannabis market to the world.
With these new law changes and the massive new market potential, Endexx via Go Green Global can now position itself to quickly move inventory into the European and worldwide markets with a significant lead over potential competitors.
Endexx has long been a company known for “Science and Compliance”, with premium quality, and has received strong critical praise. In addition, CBD Unlimited made significant headway in the industry by showing distribution success establishing real estate in over 6,000 retail stores in the last two years.
Todd Davis added, “This is the big legal “Green Flag” that we have been waiting for and positioned ourselves to take full advantage. Now, with our Jamaican position, we will further target resources towards both Cannabis and CBD distribution worldwide.”
The company has recently positioned itself to expand distribution featuring a new high-quality, lower-price point CBD Unlimited product line. This new initiative accelerates expansion efforts with a value product line to attract a wider consumer base to drive strong international growth.
About Endexx Corporation and CBD Unlimited
Endexx Corporation, through its operating subsidiary CBD Unlimited, Inc., develops and distributes all-natural CBD products derived from the Cannabis Sativa plant (Hemp), containing less than 0.01% THC. Its products range from oils, capsules, topicals, and pet products, all with the shared purpose of therapeutic and pain relief for humans and pets. Phyto-Bites are CBD soft chews for animal use that are formulated to promote health and support the reduction of separation anxiety, pain, and inflammation. The science behind these products involves over half a decade of clinical research in the field and lab work in order to protect the accuracy in dosage and delivery of absorption per each serving.
Safe Harbor Notice
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief, or current expectations of the company, its directors, or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions, and other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.
For further investor and media information, please contact:
Todd Davis, Chairman, and CEO
© 2020 GlobeNewswire, Inc. All Rights Reserved.